MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.02
-0.10
-0.67%
Opening 12:32 01/15 EST
OPEN
14.04
PREV CLOSE
14.11
HIGH
14.48
LOW
13.75
VOLUME
126.03K
TURNOVER
--
52 WEEK HIGH
25.83
52 WEEK LOW
9.01
MARKET CAP
656.11M
P/E (TTM)
-3.3417
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eye Drops & Lubricants Market Segmentation 2021-2025, Product Definition, Market Share and Characteristics, Company Profiles, Product Sales, Top Revenues and SWOT Analysis
Jan 14, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Eye Drops and Lubricants Market”...
The Express Wire · 1d ago
Glaucoma Treatment Market 2021 Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to 2025
Jan 12, 2021 (The Expresswire) -- Global Glaucoma Treatment Market Research Report focuses on market size, status and forecast 2020-2025, along with this...
The Express Wire · 3d ago
Aerie Pharmaceuticals receives European approval for Roclanda
The European Commission ((EC)) has granted marketing authorisation for Aerie Pharmaceuticals's (AERI) of Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of intraocular pressure in patients with open-angle glaucoma
Seekingalpha · 4d ago
8-K: AERIE PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- AERIE PHARMACEUTICALS INC false 0001337553 0001337553 2021-01-11 2021-01-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Benzinga · 4d ago
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda(R) (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Commission (EC) has granted a marketing authorisation for Roclanda(R) (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
BusinessWire · 4d ago
Outlook on the Glaucoma Therapeutics Global Market to 2025 - Impact of COVID-19
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 12/31/2020 17:45
Is AERI A Good Stock To Buy Now?
Insider Monkey · 12/17/2020 04:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AERI. Analyze the recent business situations of Aerie Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AERI stock price target is 26.75 with a high estimate of 50.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 266
Institutional Holdings: 62.82M
% Owned: 134.19%
Shares Outstanding: 46.81M
TypeInstitutionsShares
Increased
50
4.78M
New
37
-1.02M
Decreased
50
5.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Chief Executive Officer/Director
Vicente Anido
President/Chief Operating Officer
Thomas Mitro
Co-Founder/Chief Scientific Officer
Casey Kopczynski
Chief Financial Officer/Treasurer/Secretary
Richard Rubino
General Counsel/Secretary
John LaRocca
Finance Director
Amine Sinmazisik
Vice President - Finance
Christopher Staten
Director of Marketing
Nina Ohara
Vice President
Michelle Senchyna
Other
David Hollander
Lead Director/Independent Director
Benjamin McGraw
Director
Peter McDonnell
Independent Director
Gerald Cagle
Independent Director
Richard Croarkin
Independent Director
Mechiel Du Toit
Independent Director
David Gryska
Independent Director
Michael Du Toit
Independent Director
Julie McHugh
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AERI
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.